Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
104.56
-1.07 (-1.01%)
Streaming Delayed Price
Updated: 12:17 PM EST, Dec 7, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,358,438
Open
105.58
Bid (Size)
104.55 (2)
Ask (Size)
104.57 (3)
Prev. Close
105.63
Today's Range
103.72 - 105.60
52wk Range
96.36 - 119.65
Shares Outstanding
2,531,374,696
Dividend Yield
2.79%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Double Flops For Merck's Lung Cancer Studies
Today 9:34 EST
Merck & Co Inc (NYSE: MRK) announced full results from the Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non-small cell lung cancer (NSCLC)...
Via
Benzinga
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Today 6:45 EST
From
Merck & Co., Inc.
Via
Business Wire
Performance
YTD
-5.92%
-5.92%
1 Month
+0.21%
+0.21%
3 Month
-1.81%
-1.81%
6 Month
-3.73%
-3.73%
1 Year
-4.01%
-4.01%
More News
Read More
5 Dividend Stocks That Recently Increased Their Payouts
December 06, 2023
Via
The Motley Fool
(MRK) - Analyzing Merck & Co's Short Interest
December 04, 2023
Via
Benzinga
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
Via
Talk Markets
Price Over Earnings Overview: Merck & Co
November 30, 2023
Via
Benzinga
Analyst Ratings for Merck & Co
November 29, 2023
Via
Benzinga
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
November 30, 2023
From
Merck & Co., Inc.
Via
Business Wire
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
November 29, 2023
From
Amazon.com, Inc.
Via
Business Wire
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
November 28, 2023
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Merck Announces First-Quarter 2024 Dividend
November 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
Via
Benzinga
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
November 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Biotech And Healthcare Portfolio Playbook For December 2023/24
November 27, 2023
Via
Talk Markets
Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
November 23, 2023
Via
InvestorPlace
Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
November 22, 2023
Via
Benzinga
Merck to Acquire Caraway Therapeutics, Inc.
November 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Three Solid Stocks That Still Have Plenty Of Growth Left
November 20, 2023
Via
Talk Markets
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
November 18, 2023
Via
Benzinga
Exposures
Product Safety
FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer
November 17, 2023
Via
Benzinga
Exposures
Product Safety
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
November 17, 2023
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
November 17, 2023
Via
Benzinga
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
November 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck's Gefapixant Under FDA Lens: Advisory Committee To Discuss Chronic Cough Drug's Future
November 16, 2023
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.